![]() |
|||||||||||||
|
All | Since 2019 | |
Citation | 5450 | 3969 |
h-index | 23 | 20 |
i10-index | 134 | 84 |
QUALITY OF LIFE ASSESSMENT FOR PATIENTS WITH NEUROLOGICAL PROBLEMS (THE CASE WITH INNOVATIVE PARKINSON’S DISEASE TREATMENT WITH DUODOPA©)
Vesela Karamisheva*
ABSTRACT
Parkinson's disease is the second most common neurodegenerative disorder and the most common movement disorder. The progression of Parkinson's disease and the degree of impairment vary from individual to individual. Duodopa is an intestinal gel and contains 20 mg levopa and 5 mg carbidopa. It is indicated for the treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results. In order to assess the quality of life of patients with Parkinson that are taking Duodopa, the eight-item Parkinson‟ s disease questionnaire (PQD-8) was applied. Duodopa gastro-intestinal gel is a modern and innovative drug which positively effects and improves patients quality of life. Keywords: Parkinson, QoL, Duodopa. [Download Article] [Download Certifiate] |